The New Spider-Man: Sony and Marvel Bet Big on Tom Holland
After much speculation and debate, Marvel has finally revealed who will play Peter Parker in its next Spider-Man reboot — and it’s not a name you’ll be likely to recognize: 19-year-old Tom Holland.
Who? Exactly.
Significantly more cherubic than the last two stars cast in the role — Tobey Maguire and Andrew Garfield — Holland appeared in the 2012 movie The Impossible and had a stint in the title role of the London production of Billy Elliott. Now he’ll be the web-slinging superhero, starting with a relatively small role in next year’s Captain America: Civil War and then in an as-yet-unnamed Spider-Man movie.
Marvel had said they would be casting someone more in line with Spidey’s actual age. In the comics and films, Parker is ostensibly an 18-year-old high school senior, but Maguire was 27 when he first donned the mask, while Garfield was 28.
Related: Sony Spins a New Spider-Man Strategy with Disney
The very fact that Marvel was able to cast anyone in the role at all was thanks to a protracted negotiations with Spider-Man’s cinematic rights-holder, Sony. Finally clinching this deal allows Marvel to bring have Spider-Man play his pivotal and necessary role in Civil War, a comic-book story arc adored by critics and fans alike.
But as much as fans might have riding on Holland’s Spider-Man, Marvel and Sony are counting on him even more: They’re effectively betting hundreds of millions of dollars on the little-known actor, and hoping he can breathe new life into a franchise that, while is generated $1.5 billion in U.S. box office sales and about $4 billion worldwide, has seen dwindling returns over time.
The first Spider-Man movie starring Holland is slated to be released on July 28, 2017.
Spider-Man (2002): $403,706,375
Spider-Man 2 (2004): $373,585,825
Spider-Man 3 (2007): $336,530,303
The Amazing Spider-Man (2012): $262,030,663
The Amazing Spider-Man 2 (2014): $202,853,933
Chart of the Day: Why US Fertility Rates Are Falling
U.S. fertility rates have fallen to record lows for two straight years. “Because the fertility rate subtly shapes many major issues of the day — including immigration, education, housing, the labor supply, the social safety net and support for working families — there’s a lot of concern about why today’s young adults aren’t having as many children,” Claire Cain Miller explains at The New York Times’ Upshot. “So we asked them.”
Here are some results of the Times’ survey, conducted with Morning Consult. Read the full Times story for more details.
A Record Low 47% of US Adults Say They're 'Extremely Proud' to Be American
Gallup says that, for the first time in the 18 years it’s been asking U.S. adults how proud they are to be Americans, fewer than half say they are "extremely proud." Just 47 percent now say they’re extremely proud, down from 70 percent in 2003.
Another 25 percent say they’re “very proud” — but the combined 72 percent who say they’re extremely or very proud is also the lowest Gallup has recorded. Pride levels among liberals and Democrats have plunged since 2017. Overall, 74 percent of Republicans and just 32 percent of Democrats call themselves “extremely proud” to be American.
Pfizer Has Raised Prices on 100 of Its Products
Weeks after President Trump said that drugmakers were about to implement “voluntary massive drops in prices” — reductions that have yet to materialize — Pfizer has raised prices on 100 of its products, The Financial Times’s David Crow reports:
“The increases were effective as of July 1 and in most cases were more than 9 per cent — well above the rate of inflation in the US, which is running at about 2 per cent. … Pfizer, the largest standalone drugmaker in the US, did decrease the prices of five products by between 16 per cent and 44 per cent, according to the figures.”
Crow notes that Pfizer also raised prices on many of its medicines in January, meaning that some prices have been hiked by nearly 20 percent this year. The drugmaker said that it was only changing prices on 10 percent of its medicines and that list prices did not reflect what most patients or insurers actually paid. The net price increase after rebates and discounts was expected to be in the “low single digits,” the company told the FT.
Chart of the Day: Pass-Through Tax Deductions Made Easy
The Republican tax overhaul was supposed to simplify the tax code, but most experts say it fell well short of the goal. Martin Sullivan, chief economist at Tax Analysts, tweeted out a chart of the analysis required to determine whether income qualifies for the passthrough tax deduction of 20 percent, and as you’ll see, it’s anything but simple.
A Conservative Bashes GOP Dysfunction on Spending Cuts
Brian Riedl, a senior fellow at the conservative Manhattan Institute, offers a blistering critique of congressional Republican’s problems cutting spending:
Since the Republicans took the House in 2011, nearly every annual budget blueprint has promised to balance the budget within a decade with anywhere from $5 trillion to $8 trillion in spending cuts. And yet, you may have noticed, the budget has not moved towards balance. This is because the budget merely sets a broad fiscal goal. To actually cut spending, Congress must follow up with specific legislation to reform Medicare, Medicaid, and all the other targeted programs. In reality, most lawmakers who pass these budgets have no intention whatsoever of cutting this spending. As soon as the budget is passed, the targets are forgotten. The spending-cut legislation is never even drafted, much less voted on.
The annual budget exercise is thus a cynical exercise in symbolism. Congress calculates how much spending must be cut over ten years to balance the budget. Then they pass legislation setting a goal of cutting that amount. Then they move on to other business. It’s like a baseball team announcing that they voted to win the next World Series, and then not showing up to play the season.
Read the full piece at National Review.